Sei Investments Co. Has $10.49 Million Stake in Abivax SA Sponsored ADR $ABVX

Sei Investments Co. raised its stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 8.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 94,220 shares of the company’s stock after acquiring an additional 7,067 shares during the period. Sei Investments Co. owned about 0.12% of Abivax worth $10,494,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ABVX. TCG Crossover Management LLC boosted its stake in shares of Abivax by 17.4% in the 3rd quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock valued at $603,774,000 after purchasing an additional 1,055,000 shares in the last quarter. UBS Group AG increased its position in shares of Abivax by 2,561.0% during the 3rd quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after purchasing an additional 4,293,606 shares in the last quarter. Darwin Global Management Ltd. lifted its holdings in Abivax by 0.4% during the 4th quarter. Darwin Global Management Ltd. now owns 3,178,501 shares of the company’s stock valued at $439,714,000 after purchasing an additional 14,000 shares during the last quarter. Morgan Stanley lifted its holdings in Abivax by 114.3% during the 4th quarter. Morgan Stanley now owns 3,151,994 shares of the company’s stock valued at $425,062,000 after purchasing an additional 1,681,277 shares during the last quarter. Finally, Vestal Point Capital LP boosted its position in Abivax by 90.0% in the fourth quarter. Vestal Point Capital LP now owns 1,900,000 shares of the company’s stock valued at $256,224,000 after buying an additional 900,000 shares in the last quarter. 47.91% of the stock is owned by institutional investors.

Abivax Trading Up 0.5%

ABVX opened at $124.92 on Friday. Abivax SA Sponsored ADR has a 1-year low of $67.09 and a 1-year high of $148.83. The stock has a market capitalization of $10.90 billion, a PE ratio of -23.98 and a beta of 0.87. The firm has a 50-day moving average price of $118.54 and a two-hundred day moving average price of $118.41.

Abivax (NASDAQ:ABVX) last announced its earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.23. The company had revenue of $1.56 million for the quarter, compared to analyst estimates of $0.40 million. On average, research analysts predict that Abivax SA Sponsored ADR will post -3.22 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Abivax in a research note on Tuesday, June 30th. Truist Financial boosted their target price on Abivax from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Thursday, July 2nd. Citigroup restated an “outperform” rating on shares of Abivax in a research report on Tuesday, June 2nd. BTIG Research raised their price target on Abivax from $150.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Finally, Wedbush lifted their price objective on Abivax from $90.00 to $110.00 and gave the company a “neutral” rating in a research report on Tuesday, June 30th. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $156.50.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.